Zenas BioPharma (ZBIO) Expected to Announce Quarterly Earnings on Wednesday

Zenas BioPharma (NASDAQ:ZBIO) is expected to be releasing its Q4 2025 results before the market opens on Wednesday, February 11th. Analysts expect Zenas BioPharma to post earnings of ($1.22) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 12, 2026 at 9:30 AM ET.

Zenas BioPharma (NASDAQ:ZBIO) last announced its earnings results on Wednesday, November 12th. The company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.35).

Zenas BioPharma Stock Up 3.1%

Shares of ZBIO opened at $22.48 on Tuesday. The stock has a 50 day moving average price of $28.59 and a 200 day moving average price of $25.48. Zenas BioPharma has a one year low of $6.11 and a one year high of $44.60. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.66 and a current ratio of 5.66. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -3.18 and a beta of -1.47.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Wedbush reiterated an “outperform” rating and issued a $45.00 target price on shares of Zenas BioPharma in a research report on Monday, December 22nd. Jefferies Financial Group reaffirmed a “buy” rating and set a $48.00 price objective on shares of Zenas BioPharma in a research note on Tuesday, January 6th. HC Wainwright reiterated a “buy” rating on shares of Zenas BioPharma in a report on Tuesday, December 16th. Evercore began coverage on shares of Zenas BioPharma in a research note on Wednesday, November 26th. They issued an “outperform” rating and a $55.00 target price on the stock. Finally, Wall Street Zen lowered Zenas BioPharma from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Zenas BioPharma currently has an average rating of “Moderate Buy” and a consensus target price of $43.14.

Insider Buying and Selling at Zenas BioPharma

In other news, CEO Leon O. Moulder, Jr. purchased 57,000 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was acquired at an average price of $17.96 per share, for a total transaction of $1,023,720.00. Following the acquisition, the chief executive officer directly owned 423,155 shares of the company’s stock, valued at approximately $7,599,863.80. This represents a 15.57% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders have purchased 157,000 shares of company stock valued at $2,662,720. Corporate insiders own 16.50% of the company’s stock.

Hedge Funds Weigh In On Zenas BioPharma

Several large investors have recently made changes to their positions in ZBIO. Quarry LP increased its holdings in Zenas BioPharma by 34.5% in the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after purchasing an additional 291 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Zenas BioPharma in the third quarter valued at $30,000. BNP Paribas Financial Markets raised its holdings in shares of Zenas BioPharma by 120.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock valued at $70,000 after buying an additional 1,716 shares during the period. Sei Investments Co. acquired a new position in Zenas BioPharma during the 2nd quarter worth about $118,000. Finally, Bank of America Corp DE boosted its holdings in Zenas BioPharma by 32.3% during the 2nd quarter. Bank of America Corp DE now owns 13,991 shares of the company’s stock valued at $136,000 after acquiring an additional 3,412 shares during the period.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.